Business

Mass. Mover

Ironwood stock posts a 3.3 percent gain

 Ironwood Pharmaceuticals is based in Cambridge.

DAVID L. RYAN/GLOBE STAFF/FILE 2012

Ironwood Pharmaceuticals is based in Cambridge.

Advertisement

Ironwood Pharmaceuticals Inc. on Monday said that its new drug for irritable bowel syndrome with constipation is now available in the United States, marketed as Linzess (the trade name for linaclotide). It is estimated that irritable bowel syndrome afflicts 30 million to 40 million Americans. The stock rose Monday, fell Tuesday and Wednesday, then gained 3.2 percent Thursday. On Tuesday, Zacks upgraded the shares to “outperform,” with a $12 target price, Jagsreport.com said.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.